Pioneers in early and reliable Alzheimer's disease diagnostics

The cerebrospinal fluid (CSF) biomarkers, that were first developed by Fujirebio more than 25 years ago, have evolved over time from research biomarkers into specialized diagnostic testing tools, and from manual usage by early adopters to a widespread implementation in fully automated routine testing today.

Diagnosis for Alzheimer’s disease using CSF samples allows the detection of four proteins: two forms of amyloid (Aβ1-42 and Aβ1-40) proteins and two forms of Tau (Total Tau and phospho-Tau) proteins. If a patient has Alzheimer’s disease, then these proteins will be present in abnormally low (Aβ1-42 and Aβ1-42/Aβ1-40 ratio) and high (Total Tau and phospho-Tau) levels. The Aβ1-42 levels and the Aβ1-42/Aβ1-40 ratio will even be low long before the symptoms of the disease start to show.

In the clinical community today, there are high hopes for the use of blood-based testing for even simpler and potentially more widespread testing for Alzheimer’s disease in clinical routine. Plasma-based biomarkers for the two amyloid (Aβ1-42 and Aβ1-40) proteins and for the phospho-Tau protein are already available from Fujirebio for fully automated testing (for research use only). But research continues at the Fujirebio Neuro Center of Excellence, having led, for example, to the release of new assays for two promising biomarkers, NPTX2 and sTREM2, both for research use only.

This page collects resources and information about how Fujirebio contributes and collaborates closely with the international clinical community and partner organizations to develop the neurodegeneration diagnostic tools of the future.

 
A Neurochemist's search to save memories - Christa's and Charlotte's story about Alzheimer's disease 

Meet Dr. Charlotte Teunissen, Professor in Neurochemistry, and her lifelong friend Christa Reinhoudt, diagnosed with Alzheimer's disease in Charlotte's own laboratory.

Hear them talk about the difficult acceptance of the diagnosis and how to live with the disease. And hear about partnering in the search for earlier and better diagnostic testing solutions.

 

 

1. World Alzheimer Report 2015

 
Read more about our engagement in advancing Alzheimer's disease testing below or contact us today
 

Insights

Did you already read our popular clinical booklet?

Download the latest edition of our clinical booklet giving a detailed overview of the current state and challenges of early Alzheimer's disease diagnostics

Download booklet

Webinars

Webinar (01:04:39)

Webinar replay - Possible applications for novel CSF biomarkers

Webinar (01:04:09)

Webinar replay - Preparing for the future of plasma based Alzheimers disease diagnostics

Webinar (00:50:09)

Webinar replay - CSF-based biomarkers to support the diagnosis of Alzheimer’s disease

Did you already read our popular clinical booklet?

Download the latest edition of our clinical booklet giving a detailed overview of the current state and challenges of early Alzheimer's disease diagnostics

Download booklet

Veuillez confirmer que vous êtes un professionnel de la santé

Le contenu de ce site web est en partie réservé aux professionnels de santé qui sont directement impliqués dans la fourniture de services de soins de santé aux patients. Si vous êtes un professionnel de santé et que vous disposez de tous les droits d'accès, veuillez confirmer en cliquant sur le bouton 'oui'.

Choose your country or region

Once you have made this selection we will show you only the content that is relevant for your country. You can change this setting any time by clicking on the flag in the top toolbar of our website and choosing another country.
The content of this website is in part restricted to healthcare professionals who are directly involved in the provision of healthcare services to patients. If you are a health professional and you have full access rights, please check this box and confirm below.